Achaogen Inc
Most Recent
Why Achaogen Stock Fell Steeply Yesterday
Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.
How Analysts View BioMarin Pharmaceuticals and Peers in April
Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.
Cash Flows and Valuation Metrics of BioMarin Pharmaceuticals
BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.
Analysts’ Ratings for Spark Therapeutics and Its Peers in April 2018
Of the 20 analysts covering Spark Therapeutics in April 2018, four have given the stock “strong buy” recommendations.